Slingshot members are tracking this event:

FDA Approves Design for Global Blood's (GBT) Phase 3 Hope Trial Evaluating GBT440 in Sickle Cell Disease

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 24, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fda, Phase 3, Hope Trial, Gbt440, Design Approval, Sickle Cell Disease